StonvexLoading…
StonvexStonvexStonvexCore line items from EMR's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Annual 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $8.91B | $4.35B | $18.02B | $4.55B |
Operating Income | $1.57B | $775.00M | $2.93B | $2.14B |
Net Income | $1.22B | $605.00M | $2.29B | $586.00M |
EPS (Diluted) | $2.17 | $1.07 | $4.04 | $1.04 |
Total Assets | $42.09B | $41.94B | $41.96B | $42.52B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $1.79B | $1.75B | $1.54B | $2.22B |
Free Cash Flow OCF − CapEx | $1.30B | $602.00M | $2.67B | $1.82B |
Shares Outstanding | 560.10M | 562.00M | 562.80M | 562.80M |